Journal article
Customized Viral Immunotherapy for HPV-Associated Cancer
Abstract
The viral-transforming proteins E6 and E7 make human papillomavirus-positive (HPV+) malignancies an attractive target for cancer immunotherapy. However, therapeutic vaccination exerts limited efficacy in the setting of advanced disease. We designed a strategy to induce substantial specific immune responses against multiple epitopes of E6 and E7 proteins based on an attenuated transgene from HPV serotypes 16 and 18 that is incorporated into …
Authors
Atherton MJ; Stephenson KB; Pol J; Wang F; Lefebvre C; Stojdl DF; Nikota JK; Dvorkin-Gheva A; Nguyen A; Chen L
Journal
Cancer Immunology Research, Vol. 5, No. 10, pp. 847–859
Publisher
American Association for Cancer Research (AACR)
Publication Date
October 1, 2017
DOI
10.1158/2326-6066.cir-17-0102
ISSN
2326-6066
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Adenoviruses, HumanAnimalsCancer VaccinesCell Line, TumorCytokinesCytotoxicity, ImmunologicDisease Models, AnimalEpitopes, T-LymphocyteFemaleGenetic VectorsHumansImmunotherapyMiceMutationNeoplasmsOncogene Proteins, ViralOncolytic VirotherapyPapillomaviridaePapillomavirus E7 ProteinsPapillomavirus InfectionsProteolysisRecombinant Fusion ProteinsRepressor ProteinsT-Lymphocyte SubsetsTransgenesTumor BurdenTumor Suppressor Protein p53Xenograft Model Antitumor Assays